There are no prizes for guessing that we think Catalyst Biosciences' cash burn is a bit of a worry. In particular, we think its cash burn relative to its market cap suggests it isn't in a good position to keep funding growth. While not as bad as its cash burn relative to its market cap, its increasing cash burn is also a concern, and considering everything mentioned above, we're struggling to find much to be optimistic about. The measures we've considered in this article lead us to believe its cash burn is actually quite concerning, and its weak cash position seems likely to cost shareholders one way or another. An in-depth examination of risks revealed 4 warning signs for Catalyst Biosciences that readers should think about before committing capital to this stock.